0001628280-26-029505
SEC filingMobia Medical, Inc. is a commercial-stage medical device company offering the FDA-approved Vivistim Paired VNS System, the first clinically validated solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. This IPO provides capital to expand its commercial organization and R&D amid rapid revenue growth from $15.6M in 2024 to $32.0M in 2025.
Mobia Medical represents a compelling first-mover opportunity in chronic stroke recovery, addressing a massive unmet need with its Vivistim Paired VNS System—the only FDA PMA-approved Class III device for moderate-to-severe upper extremity impairments post-ischemic stroke. With stroke affecting 800K Americans annually and 4M+ chronic survivors eligible, the $30B initial TAM is backed by AHA data showing 87% ischemic strokes and persistent impairments beyond sub-acute rehab. Pivotal VNS-REHAB trial data (published in The Lancet) demonstrated 2x FMA-UE and 3x WMFT improvements vs. intensive rehab alone, with durable 1-year gains and safety profile showing <1% unresolved surgical complications. Commercial traction is accelerating: 104.8% YoY revenue growth to $32M in 2025 (81% gross margin), 700 implants (up from prior years), and Q1 2026 preliminary revenue of $11.9-12.1M (110% YoY). Physicians have performed 1,000+ implants since 2023 launch, targeting 1,500 primary/comprehensive stroke centers handling 70% of acute cases.
The $134.5M net proceeds (at $15 midpoint) fund critical scaling: $93.5M expands the 83-person sales team (40 TMs, 43 TDSs) to penetrate high-volume centers, while $18.5M supports R&D/next-gen Vivistim and clinical registries like GRASP (255 enrolled). Post-IPO capitalization shows 33.1M shares outstanding, with insiders/5% holders retaining ~57% ownership and 180-day lock-up. Pre-IPO cash of $33.6M (plus $40M 2026 notes converting at IPO) addresses going concern doubts from $46.5M 2025 net loss and $158M accumulated deficit.
Risks are notable but manageable for growth investors: single-product dependency, single-source supply (Integer for IPG, Cirtec for leads with $5.8M 5-year commitment), and reimbursement hurdles (Medicare case-by-case, most commercial plans experimental). Material weakness in per-share calculations was identified but remediated. No direct competitors exist, with moats from IP portfolio (12+ UT-licensed patents), breakthrough designation, and clinician familiarity with VNS procedures. Management's MedTech pedigrees (Foust, Ellison) position for execution amid $25B+ annual ischemic stroke burden.